A Study of BL-B01D1 + Axitinib Without or With Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 + axitinib without or with pembrolizumab (BL-B01D1 + axitinib pembrolizumab) in patients with locally advanced or metastatic renal cancer.